Display of peptides on the surface of tobacco mosaic virus particles

Current Topics in Microbiology and Immunology

Volumn 332, Issue , 2010, Pages 13-31

  Smith, M L ^a   Fitzmaurice, W P ^b   Turpen, T H ^c   Palmer, K E ^d  

^a GENENTECH INC   (United States)

^b Novici Biotech   (United States)

^c Technology Innovation Group Inc   (United States)

^d NONE

Author keywords

papillomavirus; plant; tobacco mosaic virus; vaccine; virus like particle

Indexed keywords

AZIRIDINE DERIVATIVE; BINARY ETHYLENIMINE; CANCER VACCINE; COAT PROTEIN; FORMALDEHYDE; NONHODGKIN LYMPHOMA VACCINE; PEPTIDE VACCINE; PROPIOLACTONE; UNCLASSIFIED DRUG; PEPTIDE; SUBUNIT VACCINE;

BIOTECHNOLOGICAL PRODUCTION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; DRUG STERILITY; HOST SUSCEPTIBILITY; HUMAN; INFECTION; NICOTIANA BENTHAMIANA; NONHODGKIN LYMPHOMA; NONHUMAN; PLANT GROWTH; PLANT MORPHOLOGY; PLANT VIRUS; PRIORITY JOURNAL; REVIEW; SCALE UP; TOBACCO MOSAIC VIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS RECOMBINANT; BIOSYNTHESIS; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM;

PAPILLOMAVIRIDAE; TOBACCO MOSAIC VIRUS;

PEPTIDES; TOBACCO MOSAIC VIRUS; VACCINES, SUBUNIT;

EID: 67849133693     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-70868-1_2     Document Type: Review

References (66)

1. Adams SE, Dawson KM, Gull K, et al (1987) The expression of hybrid HIV-Ty virus-like particles in yeast. Nature 329:68-70
2. Assemand E, Lacroix M, Mateescu MA (2003) L-Tyrosine prevents aggregation of therapeutic proteins by gamma-irradiation. Biotechnol Appl Biochem 38:151-156
3. Bachmann MF, Dyer MR (2004) Opinion. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 3:81-88
4. Bahnemann HG (1990) Inactivation of viral-antigens for vaccine preparation with particular reference to the application of binary ethyleneimine. Vaccine 8:299-303
5. Bendahmane M, Koo M, Karrer E, et al (1999) Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J Mol Biol 290:9-20
6. Birkett A, Lyons K, Schmidt A, et al (2002) A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70:6860-6870
7. Blackburn NK, Besselaar TG (1991) A study of the effect of chemical inactivants on the epitopes of Rift-Valley fever virus glycoproteins using monoclonal-antibodies. J Virol Methods 33:367-374
8. Bowman F, Calhoun M, White M (1967) Microbiological methods for quality control of membrane filters. J Pharm Sci 56:222-225
9. Brown F (2001) Inactivation of viruses by aziridines. Vaccine 20:322-327
10. Brown F, Meyer RF, Law M, et al (1998) A universal virus inactivant for decontaminating blood and biopharmaceutical products. Biologicals 26:39-47
11. Burke KL, Dunn G, Ferguson Met al (1988) Antigen chimeras of poliovirus as potential new vaccines. Nature 332:81-82
12. Chackerian B, Lenz P, Lowy DR, et al (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169:6120-6126
13. Clarke BE, Newton SE, Carroll AR, et al (1987) Improved immunogenicity of a peptide epitope after fusion to hepatitis-B core protein. Nature 330:381-384
14. Clarke BE, Brown AL, Grace KG, et al (1990) Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis-B virus core particles produced in bacteria. J Gen Virol 71:1109-1117
15. Corbett MK (1961) Purification of potato virus X without aggregation. Virology 15:8-15
16. Dalsgaard K, Uttenthal A, Jones TD, et al (1997) Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol 15:248-252
17. Dawson WO, Beck DL, Knorr DA, et al (1986) cDNA cloning of the complete genome of tobacco mosaic-virus and production of infectious transcripts. Proc Natl Acad Sci U S A 83:1832-1836
18. Delpeyroux F, Chenciner N, Lim A, et al (1986) A poliovirus neutralization epitope expressed on hybrid hepatitis-B surface-antigen particles. Science 233:472-475
19. Delpeyroux F, Peillon N, Blondel B, et al (1988) Presentation and immunogenicity of the hepatitis-B surface-antigen and a poliovirus neutralization antigen on mixed empty envelope particles. J Virol 62:1836-1839
20. Dreesen DW (1997) A global review of rabies vaccines for human use. Vaccine 15:S2-S6
21. Dunn DB, Hitchborn JH (1965) The use of bentonite in the purification of plant viruses. Virology 25:171-192
22. Fehr T, Skrastina D, Pumpens P, et al (1998) T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci U S A 95:9477-9481
23. Fitchen J, Beachy RN, Hein MB (1995) Plant-virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine 13:1051-1057
24. Fitzmaurice WP (2002) U.S. Patent No. 6344597
25. Garger SJ, Holtz RB, et al (2000) U.S. patent No. 6033895
26. Garger SJ, Holtz RB, et al (2001) U.S. patent No. 6303779
27. Gooding GV, Hebert TT (1967) A simple technique for purification of tobacco mosaic virus in large quantities. Phytopathology 57:1285
28. Haynes JR, Cunningham J, von Seefried A, et al (1986) Development of a genetically-engineered, candidate polio vaccine employing the self-assembling properties of the tobacco mosaic-virus coat protein. Bio/Technology 4:637-641
29. Howard G, Duberstein R (1980) A case of penetration of 0.2 um rated membrane filters by bacteria. J Parenter Drug Assoc 34:95
30. Kasermann F, Wyss K, Kempf C (2001) Virus inactivation and protein modifications by ethyleneimines. Antiviral Res 52:33-41
31. Koo M, Bendahmane M, Lettieri GA, et al (1999) Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A 96:7774-7779
32. Langeveld JPM, Brennan FR, Martínez-Torrecuadrada JL, et al (2001) Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine 19:3661-3670
33. Loor F (1967) Comparative immunogenicities of tobacco mosaic virus, protein subunits, and reaggregated protein subunits. Virology 33:215-220
34. Marbrook J, Matthews REF (1966) The differential immunogenicity of plant viral protein and nucleoproteins. Virology 28:219-228
35. Martin A, Wychowski C, Couderc T, et al (1988) Engineering a poliovirus type-2 antigenic site on a type-1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J 7:2839-2847
36. Martin J, Crossland G, Wood DJ, et al (2003) Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 84:1781-1788
37. McCormick AA, Reinl SJ, Cameron TI, et al (2003) Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 278:95-104
38. McCormick AA, Corbo T, Wykoff-Clary S et al. (2006) TMV-peptide fusion vaccines induce T-cell mediated immune responses and tumor protection in two murine models. Vaccine 24:6414-6423
39. McCormick AA, Reddy S, Reinl SJ et al. (2008) Plant-produced idiotype vaccines for the treatment of Non-Hodgkins Lymphoma: Safety and immunogenicity in a phase I clinical study. Proc. Natl. Acad. Sci. USA 105 (29):10131-10136
40. Meshi T, Ishikawa M, Motoyoshi F, et al (1986) In vitro transcription of infectious RNAs from full-length cDNAs of tobacco mosaic-virus. Proc Natl Acad Sci U S A 83:5043-5047
41. Moon S, Bin Song K (2001) Effect of gamma-irradiation on the molecular properties of ovalbumin and ovomucoid and protection by ascorbic acid. Food Chem 74:479-483
42. Moorthy VS, Good MF, Hill AV (2004) Malaria vaccine developments. Lancet 363:150-156
43. Namba K, Stubbs G (1986) Structure of tobacco mosaic-virus at 3.6-Å resolution-implications for assembly. Science 231:1401-1406
44. Offit PA, Jew PK (2003) Addressing parents concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112:1394-1401
45. Palmer KE, Benko A Doucette SA et al. (2006) Protection of rabbits against cutaneous and mucosal papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24:5516-5525
46. Patro SY, Freund E, Chang BS (2002) Protein formulation and fill-finish operations. Biotechnol Annu Rev 8:55-84
47. Perez O, Paolazzi CC (1997) Production methods for rabies vaccine. J Ind Microbiol Biotechnol 18:340-347
48. Perrin P, Morgeaux S (1995) Inactivation of DNA by beta-propiolactone. Biologicals 23:207-211
49. Pogue GP, Lindbo JA, Garger SJ, et al (2002) Making an ally from an enemy: plant virology and the new agriculture. Annu Rev Phytopathol 40:45-74
50. Pogue GP, Lindbo JA, McCulloch MJ, et al (2004) U.S. patent No.6730306 B1
51. Porta C, Spall VE, Findley KC, et al (2003) Cowpea mosaic virus-based chimaeras-effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology 310:50-63
52. Powell MF, Nguyen T, Baloian L (1998) Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol 52:238-311
53. Staczek J, Bendahmane M, Gilleland LB, et al (2000) Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa . Vaccine 18:2266-2274
54. Storni T, Ruedl C, Schwartz K, et al (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172:1777-1785
55. Sugiyama Y, Hamamoto H, Takemoto S, et al (1995) Systemic production of foreign peptides on the particle surface of tobacco mosaic-virus. FEBS Lett 359:247-250
56. Sundaram S, Auriemma M, Howard G Jr, et al (1999) Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes. PDA J Pharm Sci Technol 53:186-201
57. Timian RG, Savage SM (1966) Purification of barley stripe mosaic virus with chloroform and charcoal. Phytopathology 56:1233-1235
58. Turpen TH (1999) Tobacco mosaic virus and the virescence of biotechnology. Philos Trans R Soc Lond B Biol Sci 354:665-673
59. Turpen TH, Reinl SJ, Charoenvit Y, et al (1995) Malarial epitopes expressed on the surface of recombinant tobacco virus. Bio/Technology 13:53-57
60. Valenzuela P, Coit D, Kuo G (1985) Antigen engineering in yeast-synthesis and assembly of hybrid hepatitis-B surface antigen herpes simplex 1 gD particles. Bio/Technology 3:323-326
61. van Regenmortel MHV (1999) The antigenicity of tobacco mosaic virus. Philos Trans R Soc Lond B Biol Sci 354:559-568
62. Watson JD (1954) The structure of tobacco mosaic virus 1. X-ray evidence of a helical arrangement of sub-units around the longitudinal axis. Biochim Biophys Acta 13:10-19
63. Wesslen T, Lycke E, Olin G, et al (1957) Inactivation of poliomyelitis virus by formaldehyde. Arch Gesamte Virusforsch 7:125-135
64. Wu LG, Jiang LB, Zhou Z, et al (2003) Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 21:4390-4398
65. Wu YY, Snyder EL (2003) Safety of the blood supply: role of pathogen reduction. Blood Rev 17:111-122
66. Yusibov V, Hooper DC, Spitsin SV, et al (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155-3164